Investigation of the Effect of Origanum Majorana on Polycystic Ovary Syndrome Patients

The polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. Many studies indicated the health-supporting effects of phenolic compounds in reducing the symptoms of PCOS. The richness of Origanum Majorana in phenolic compounds may enable it to have a role in the treatment of PCOS when it is consumed as a functional drink. This study aimed to investigate the effect of Origanum Majorana on the number and size of cysts in patients with PCOS. Origanum Majorana tea (2 g of Origanum Majorana in 200 ml water) was consumed daily by ten PCOS women for two months, with monitoring of the size and number of cysts. The consumption of Origanum Majorana tea decreased the number of cysts, since there were no more patients with high cyst numbers (more than 15 cysts). Additionally, the percentage of patients with 11-15 cysts decreased to 20 percent, while an increase in the number of patients with fewer than 11 cysts was recorded (p-value Less den 0.05). On the other hand, giving Origanum majorana tea to women with PCOS reduced cyst size, the percentage of patients with very small cysts increased to 50 percent, with no patients having cysts between 8 and 15 mm. Consumption of Origanum majorana tea reduced the number and size of the PCOS lesions, indicating a therapeutic role for O. majorana in PCOS when consumed as a herbal tea. It could be said that the phenolic compounds present in Origanum Majorana tea improved the condition regardless of age. Diet and BMI can affect patients outcomes after consuming Origanum majorana tea.